BioHarvest Sciences (NASDAQ:BHST) Stock Price Up 1.4% – What’s Next?

BioHarvest Sciences Inc. (NASDAQ:BHST) shares rose 1.4% during mid-day trading on Tuesday. The stock traded as high as $1.52 and last traded at $1.47. Approximately 69,597 shares changed hands during trading, an increase of 113% from the average daily volume of 32,657 shares. The stock had previously closed at $1.45.

Analyst Ratings Changes

BHST has been the subject of a number of recent research reports. Maxim Group reduced their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Roth Capital dropped their price objective on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BioHarvest Sciences currently has a consensus rating of “Hold” and a consensus price target of $6.50.

BioHarvest Sciences Price Performance

The stock has a 50 day simple moving average of $1.92 and a two-hundred day simple moving average of $3.07. The company has a market cap of $29.23 million, a price-to-earnings ratio of -2.87 and a beta of 0.94.

BioHarvest Sciences (NASDAQ:BHST) last issued its earnings results on Monday, August 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.04). BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%. The company had revenue of $8.84 million during the quarter, compared to analysts’ expectations of $9.45 million. As a group, research analysts forecast that BioHarvest Sciences Inc. will post -0.58 EPS for the current year.

Institutional Investors Weigh In On BioHarvest Sciences

A number of hedge funds have recently modified their holdings of the company. Silverberg Bernstein Capital Management LLC acquired a new stake in BioHarvest Sciences during the first quarter worth about $113,000. True North Advisors LLC boosted its holdings in BioHarvest Sciences by 381.0% in the 1st quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock valued at $729,000 after purchasing an additional 133,085 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC acquired a new position in BioHarvest Sciences in the 4th quarter valued at about $1,945,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company developing and commercializing products made with its proprietary Botanical Synthesis technology. The company’s platform is designed to produce specific plant-based compounds, including polyphenols, without growing the entire plant. BioHarvest says the process may help generate consistent, standardized botanical ingredients for use in health and wellness products and pharmaceutical development.

The company’s principal commercial product is VINIA, a powdered whole-fruit botanical ingredient derived from red grape cells and marketed for its polyphenol content.